Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01567891 | CT Antigen TCR-redirected T Cells for Ovarian Cancer. | PHASE1 | COMPLETED | 9 | — | — | Jul 9, 2013 | Jun 6, 2017 | Jun 27, 2019 | 5 | United States |
Number of Participants with Adverse Events related to study treatment
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells. |
| Name | Type | Description |
|---|---|---|
| NYESO-1c259 T cells | BIOLOGICAL | Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion. |
Inclusion Criteria: * Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with refractory or platinum resistant disease and/or have received ≥ 2 lines of chemotherapy * Age ≥ 18 years of age * No significant immunodeficiency * Have been informed of ...